Drug intelligence / Profile preview

CTx-2000

Development stage: Unknown
Lead developer: Celosia Therapeutics
Modality: Gene Therapies

Overview

CTx-2000 is an investigational gene therapy developed by Celosia Therapeutics. It is currently in the discovery phase and has not yet entered clinical trials. The primary therapeutic focus for CTx-2000 is amyotrophic lateral sclerosis (ALS), a neurodegenerative disease affecting motor neurons. The drug is also being explored for other nervous system diseases as well as endocrinology and metabolic diseases, though specific indications beyond ALS have not been detailed publicly. As of the latest updates, no specific molecular target or mechanism of action has been disclosed for this therapy[1][2].

Beyond the preview

Go deeper on CTx-2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTx-2000.

Explore the full profile